$AWH
Aspira Women's Health Inc.

2013 Q1 Form 10-K Financial Statement

#000119312513087647 Filed on March 01, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q4 2012
Revenue $328.0K $1.140M $2.094M
YoY Change 5.13% 31.03% 8.89%
Cost Of Revenue $37.00K $30.00K $131.0K
YoY Change -2.63% 50.0% 1.55%
Gross Profit $291.0K $1.110M $1.963M
YoY Change 6.2% 32.14% 9.42%
Gross Profit Margin 88.72% 97.37% 93.74%
Selling, General & Admin $2.409M $2.060M $9.161M
YoY Change 21.3% -25.09% -34.79%
% of Gross Profit 827.84% 185.59% 466.68%
Research & Development $484.0K $330.0K $2.216M
YoY Change 7.08% -71.79% -58.86%
% of Gross Profit 166.32% 29.73% 112.89%
Depreciation & Amortization $21.00K $30.00K $86.00K
YoY Change 0.0% 50.0% 11.69%
% of Gross Profit 7.22% 2.7% 4.38%
Operating Expenses $2.893M $2.390M $11.38M
YoY Change 18.66% -39.03% -41.46%
Operating Profit -$2.602M -$1.280M -$9.414M
YoY Change 20.24% -58.44% -46.64%
Interest Expense $0.00 $0.00 $206.0K
YoY Change -100.0% -100.0% -47.98%
% of Operating Profit
Other Income/Expense, Net $29.00K -$90.00K -$182.0K
YoY Change -231.82% -1000.0% 83.84%
Pretax Income -$2.571M -$1.380M -$7.052M
YoY Change 44.76% -56.05% -60.15%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.571M -$1.380M -$7.146M
YoY Change 44.76% -56.05% -59.83%
Net Earnings / Revenue -783.84% -121.05% -341.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$169.1K -$91.21K -$476.3K
COMMON SHARES
Basic Shares Outstanding 15.20M shares 15.01M shares
Diluted Shares Outstanding 15.01M shares

Balance Sheet

Concept 2013 Q1 2012 Q4 2012
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.800M $8.000M $8.000M
YoY Change -70.85% -64.44% -64.44%
Cash & Equivalents $5.834M $8.007M $8.000M
Short-Term Investments
Other Short-Term Assets $400.0K $300.0K $300.0K
YoY Change 0.0% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables $184.0K $137.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.377M $8.492M $8.500M
YoY Change -68.59% -62.91% -62.88%
LONG-TERM ASSETS
Property, Plant & Equipment $121.0K $142.0K $100.0K
YoY Change -39.5% -34.26% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.000K $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $129.0K $142.0K $100.0K
YoY Change -35.5% -34.86% -50.0%
TOTAL ASSETS
Total Short-Term Assets $6.377M $8.492M $8.500M
Total Long-Term Assets $129.0K $142.0K $100.0K
Total Assets $6.506M $8.634M $8.600M
YoY Change -68.26% -62.64% -62.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $794.0K $525.0K $500.0K
YoY Change 13.43% -60.56% -61.54%
Accrued Expenses $964.0K $1.074M $1.100M
YoY Change -58.09% -58.56% -57.69%
Deferred Revenue
YoY Change
Short-Term Debt $1.106M $1.106M $1.100M
YoY Change -84.2% -84.2% -84.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.573M $3.197M $3.200M
YoY Change -66.61% -72.14% -72.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $800.0K $800.0K
YoY Change -36.36% 1438.46% -38.46%
Total Long-Term Liabilities $700.0K $800.0K $800.0K
YoY Change -36.36% 1438.46% -38.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.573M $3.197M $3.200M
Total Long-Term Liabilities $700.0K $800.0K $800.0K
Total Liabilities $4.229M $3.967M $4.000M
YoY Change -64.16% -68.89% -68.75%
SHAREHOLDERS EQUITY
Retained Earnings -$326.0M -$323.4M
YoY Change 2.26%
Common Stock $15.00K $15.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.277M $4.667M $4.700M
YoY Change
Total Liabilities & Shareholders Equity $6.506M $8.634M $8.600M
YoY Change -68.26% -62.64% -62.77%

Cashflow Statement

Concept 2013 Q1 2012 Q4 2012
OPERATING ACTIVITIES
Net Income -$2.571M -$1.380M -$7.146M
YoY Change 44.76% -56.05% -59.83%
Depreciation, Depletion And Amortization $21.00K $30.00K $86.00K
YoY Change 0.0% 50.0% 11.69%
Cash From Operating Activities -$2.173M -$2.430M -$10.40M
YoY Change -17.09% -48.84% -33.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $14.00K
YoY Change -100.0% -85.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.830M
YoY Change
Cash From Investing Activities $0.00 $0.00 $1.816M
YoY Change -100.0% -1934.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -5.900M -5.888M
YoY Change -100.0% -59100.0% -138.64%
NET CHANGE
Cash From Operating Activities -2.173M -2.430M -10.40M
Cash From Investing Activities 0.000 0.000 1.816M
Cash From Financing Activities 0.000 -5.900M -5.888M
Net Change In Cash -2.173M -8.330M -14.47M
YoY Change -17.19% 75.74% 3188.64%
FREE CASH FLOW
Cash From Operating Activities -$2.173M -$2.430M -$10.40M
Capital Expenditures $0.00 $0.00 $14.00K
Free Cash Flow -$2.173M -$2.430M -$10.41M
YoY Change -17.38% -48.84% -33.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15200079 shares
CY2009Q4 vrml Convertible Notes Conversion Rate Number Of Common Stock Shares
ConvertibleNotesConversionRateNumberOfCommonStockShares
47 shares
CY2009Q4 vrml Principal Amount Of Notes To Be Considered In Conversion Rate
PrincipalAmountOfNotesToBeConsideredInConversionRate
1000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1092374 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
4616000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1924
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10539000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.13
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22914000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
849485 shares
CY2011Q4 us-gaap Business Acquisition Cost Of Acquired Entity Purchase Price
BusinessAcquisitionCostOfAcquiredEntityPurchasePrice
435000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
317000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42443000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
553000
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1617000
CY2009Q4 vrml Principal Balance Of Exchange Notes
PrincipalBalanceOfExchangeNotes
135000
CY2012Q2 dei Entity Public Float
EntityPublicFloat
30444327
CY2012Q4 vrml Line Of Credit Facility Principal Repayment
LineOfCreditFacilityPrincipalRepayment
5894000
CY2009Q4 vrml Convertible Notes Conversion Rate Number Of Common Stock Shares
ConvertibleNotesConversionRateNumberOfCommonStockShares
55 shares
CY2009Q4 vrml Cash Payments
CashPayments
2195000
CY2009Q4 vrml Common Stock Shares Issued In Lieu Of Cash Payments
CommonStockSharesIssuedInLieuOfCashPayments
9044 shares
CY2009Q4 vrml Principal Amount Of Notes To Be Considered In Conversion Rate
PrincipalAmountOfNotesToBeConsideredInConversionRate
1000
CY2009Q4 vrml Principal Balance Of Exchange Notes
PrincipalBalanceOfExchangeNotes
7100000
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1013983 shares
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
530000
CY2011Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
628675 shares
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55210000
CY2011Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000
CY2011Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
7000000
CY2011Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700 pure
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
10359000
CY2011Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
184000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
268000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
76000
CY2011Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
8000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14900831 shares
CY2011Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
195012 shares
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
279000
CY2011Q4 us-gaap Liabilities
Liabilities
12752000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1331000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10777000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2592000
CY2011Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
65000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11476000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
930060 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
52000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316299000
CY2011Q4 us-gaap Assets
Assets
23111000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.97
CY2011Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
1025000
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
99000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23111000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22477000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14900831 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-153000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1224000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
22893000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55218000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
314000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
326796000
CY2011Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
8000
CY2011Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
641000
CY2011Q4 vrml Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
11158000
CY2011Q4 vrml Computer Hardware And Software Gross
ComputerHardwareAndSoftwareGross
251000
CY2011Q4 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsAndExpirationsInPeriodWeightedAverageExercisePrice
23.04
CY2011Q4 vrml Debt Redemption Price Percent Of Principal Amount
DebtRedemptionPricePercentOfPrincipalAmount
1.050 pure
CY2011Q4 vrml Escrow Amount
EscrowAmount
1830000
CY2011Q4 vrml Percentage Threshold Closing Sale Price Of Common Stock Higher Than Conversion Price
PercentageThresholdClosingSalePriceOfCommonStockHigherThanConversionPrice
2.000 pure
CY2011Q4 vrml Warrant Liability
WarrantLiability
378000
CY2011Q4 vrml Demonstration Equipment
DemonstrationEquipment
30000
CY2011Q4 vrml Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
303000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
348000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
94000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
405000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57296000
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
22471 shares
CY2012Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1106000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
606215 shares
CY2012Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700 pure
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
4667000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
193000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
531000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
17000
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
8000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.73
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15200079 shares
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
10900000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
236000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
398650 shares
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
39000
CY2012Q4 us-gaap Liabilities
Liabilities
3967000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
525000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10897000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46918000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
492000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1431000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-323445000
CY2012Q4 us-gaap Assets
Assets
8634000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.17
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.23
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
137000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8634000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8007000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15200079 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1074000
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
65000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3197000
CY2012Q4 vrml Escrow Amount
EscrowAmount
2000000
CY2012Q4 vrml Claim For Indemnification
ClaimForIndemnification
307000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
770000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
8492000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57304000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
263000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328097000
CY2012Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
8000
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
464000
CY2012Q4 vrml Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
8955000
CY2012Q4 vrml Computer Hardware And Software Gross
ComputerHardwareAndSoftwareGross
114000
CY2012Q4 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsAndExpirationsInPeriodWeightedAverageExercisePrice
21.57
CY2012Q4 vrml Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.000 pure
CY2012Q4 vrml Line Of Credit Facility Outstanding Principal Balance After Additional Reduction
LineOfCreditFacilityOutstandingPrincipalBalanceAfterAdditionalReduction
6000000
CY2012Q4 vrml Line Of Credit Facility Additional Reduction In Outstanding Principal Balance
LineOfCreditFacilityAdditionalReductionInOutstandingPrincipalBalance
1000000
CY2012Q4 vrml Demonstration Equipment
DemonstrationEquipment
33000
CY2012Q4 vrml Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
133000
CY2010Q1 vrml Payment Of Accrued Interest
PaymentOfAccruedInterest
362000
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20206000
CY2009Q4 vrml Issuance Of Common Stock Shares In Exchange For Notes
IssuanceOfCommonStockSharesInExchangeForNotes
6750 shares
CY2009Q4 vrml Debt Conversion Costs
DebtConversionCosts
69000
CY2009Q4 vrml Accrued And Unpaid Interest
AccruedAndUnpaidInterest
8000
CY2011Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5000000
CY2012Q4 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
5894000
CY2009Q4 vrml Issuance Of Common Stock Shares In Exchange For Notes
IssuanceOfCommonStockSharesInExchangeForNotes
421667 shares
CY2009Q4 vrml Repayments Of Principal On Notes Payable
RepaymentsOfPrincipalOnNotesPayable
2365000
CY2009Q4 vrml Payment Of Accrued Interest
PaymentOfAccruedInterest
140000
CY2009Q4 vrml Debt Conversion Costs
DebtConversionCosts
819000
CY2009Q4 vrml Accrued And Unpaid Interest
AccruedAndUnpaidInterest
589000
CY2010Q4 vrml Debt Remaining Principal Amount
DebtRemainingPrincipalAmount
0
CY2010Q4 vrml Notes Payable Aggregate Principal Amount Outstanding
NotesPayableAggregatePrincipalAmountOutstanding
5000000
CY2011Q4 vrml Debt Remaining Principal Amount
DebtRemainingPrincipalAmount
0
CY2011Q4 vrml Number Of Consecutive Trading Day
NumberOfConsecutiveTradingDay
P30D
CY2011Q4 vrml Minimum Number Of Trading Days
MinimumNumberOfTradingDays
P20D
CY2010 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M22D
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-207000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-17641000
CY2011 us-gaap Debtor Reorganization Items Legal And Advisory Professional Fees
DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees
96000
CY2011 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1469000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20206000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17787000
CY2011 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
3286000
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
238000
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
253000
CY2011 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1043000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
CY2011 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21833 shares
CY2011 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
129000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-94000
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15581000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
CY2011 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
9000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-497000
CY2011 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
5000000
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02 pure
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20206000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-437000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8509000
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-462000
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14249570 shares
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-37000
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17790000
CY2011 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5539000
CY2011 us-gaap Licenses Revenue
LicensesRevenue
454000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5387000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15240000
CY2011 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
4000
CY2011 us-gaap Operating Expenses
OperatingExpenses
19435000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17696000
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14249570 shares
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
129000
CY2011 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
129000
CY2011 us-gaap Revenues
Revenues
1923000
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.17 pure
CY2011 us-gaap Depreciation
Depreciation
77000
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2011 us-gaap Gross Profit
GrossProfit
1794000
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14249570 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1260820 shares
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-17790000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-99000
CY2011 us-gaap Interest Paid Net
InterestPaidNet
462000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
191930 shares
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
3000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue
1218000
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17790000
CY2011 us-gaap Interest Expense
InterestExpense
396000
CY2011 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17790000
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantOptionsCancelledInPeriod
89522 shares
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantedInPeriod
274295 shares
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGrantedInPeriod
191930 shares
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledInPeriod
89522 shares
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsCancelledInPeriod
20000 shares
CY2011 vrml Net Income Loss Available To Common Stockholders Per Share Basic
NetIncomeLossAvailableToCommonStockholdersPerShareBasic
1.25
CY2011 vrml Net Income Loss Available To Common Stockholders Per Share Diluted
NetIncomeLossAvailableToCommonStockholdersPerShareDiluted
1.25
CY2011 vrml Earnings Per Share Dilutive Effect Of Stock Options
EarningsPerShareDilutiveEffectOfStockOptions
CY2011 vrml Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants
0.01 pure
CY2011 vrml Change In Fair Value And Gain From Exercise Of Warrants Net
ChangeInFairValueAndGainFromExerciseOfWarrantsNet
378000
CY2011 vrml Common Stock Issued For Debtor S Incentive Plan
CommonStockIssuedForDebtorSIncentivePlan
1656000
CY2011 vrml Common Stock Issued For Restricted Stock Awards
CommonStockIssuedForRestrictedStockAwards
587000
CY2011 vrml Increase Decrease In Reorganization Items
IncreaseDecreaseInReorganizationItems
-384000
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Prices
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices
1.55
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Prices
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrices
2.40
CY2011 vrml Warrants Issued For Services
WarrantsIssuedForServices
4000
CY2011 vrml Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.09 pure
CY2011 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Reduction In Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantReductionInGrant
28605 shares
CY2012 dei Trading Symbol
TradingSymbol
VRML
CY2012 dei Entity Registrant Name
EntityRegistrantName
VERMILLION, INC.
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-52000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-9414000
CY2012 us-gaap Debtor Reorganization Items Legal And Advisory Professional Fees
DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees
-88000
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1640000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M6D
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6993000
CY2012 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
86000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1281000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.04 pure
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
120000
CY2012 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
465000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2292000
CY2012 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
331000
CY2012 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
566000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8333 shares
CY2012 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
131000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-94000
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. We maintain our cash and cash equivalents in recognized financial institutions in the United States. We have not experienced any losses associated with our deposits of cash and cash equivalents. We do not invest in derivative instruments or engage in hedging activities.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Our accounts receivable are derived from sales made to a customer located in North America. We perform ongoing credit evaluations of our customer&#x2019;s financial condition and generally do not require collateral. We maintain an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Our accounts receivable at December&#xA0;31, 2012 and 2011 and revenues for the years then ended are from one customer.</font></p> </div>
CY2012 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2012-10-07
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2012 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
1830000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10398000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1816000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2012 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
5000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-61000
CY2012 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
5000000
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03 pure
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14470000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4508000
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31000
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M7D
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15010868 shares
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
153000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7146000
CY2012 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4653000
CY2012 us-gaap Licenses Revenue
LicensesRevenue
454000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2216000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5888000
CY2012 us-gaap Line Of Credit Facility Periodic Payment Principal
LineOfCreditFacilityPeriodicPaymentPrincipal
106000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7052000
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15010868 shares
CY2012 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
35000
CY2012 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
7000
CY2012 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
14000
CY2012 us-gaap Operating Expenses
OperatingExpenses
11377000
CY2012 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
710000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
110000
CY2012 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
1830000
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M23D
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
131000
CY2012 us-gaap Revenues
Revenues
2094000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.31 pure
CY2012 us-gaap Depreciation
Depreciation
86000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2012 us-gaap Gross Profit
GrossProfit
1963000
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15010868 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1163708 shares
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-7146000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-182000
CY2012 us-gaap Interest Paid Net
InterestPaidNet
227000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
558300 shares
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue
525000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7146000
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying our consolidated financial statements include assumptions regarding variables used in calculating the fair value of our equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.</font></p> </div>
CY2012 vrml Defined Benefit Plan Percentage Of Eligible Bonus Deferral Allowed For Deferred Compensation Plan Maximum
DefinedBenefitPlanPercentageOfEligibleBonusDeferralAllowedForDeferredCompensationPlanMaximum
0.900 pure
CY2012 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-2086000
CY2012 us-gaap Interest Expense
InterestExpense
206000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7146000
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantOptionsCancelledInPeriod
387653 shares
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsGrantedInPeriod
212500 shares
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGrantedInPeriod
558300 shares
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledInPeriod
387653 shares
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsCancelledInPeriod
28001 shares
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Prices
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrices
0.75
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Prices
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrices
1.54
CY2012 vrml Agreement Entry Month And Year
AgreementEntryMonthAndYear
2011-11
CY2012 vrml Warrants Issued For Services
WarrantsIssuedForServices
14000
CY2012 vrml Net Income Loss Available To Common Stockholders Per Share Basic
NetIncomeLossAvailableToCommonStockholdersPerShareBasic
0.48
CY2012 vrml Net Income Loss Available To Common Stockholders Per Share Diluted
NetIncomeLossAvailableToCommonStockholdersPerShareDiluted
0.48
CY2012 vrml Royalty Rate Percentage
RoyaltyRatePercentage
0.02 pure
CY2012 vrml Earnings Per Share Dilutive Effect Of Stock Options
EarningsPerShareDilutiveEffectOfStockOptions
CY2012 vrml Amount Of Application For Licensed Laboratory Test Commercialized
AmountOfApplicationForLicensedLaboratoryTestCommercialized
1000000
CY2012 vrml Common Stock Issued For Restricted Stock Awards
CommonStockIssuedForRestrictedStockAwards
715000
CY2012 vrml Contingent Liability Claim
ContingentLiabilityClaim
1000000
CY2012 vrml Discussions With Quest Diagnostics In Regard Of Achievement Of Additional Amount
DiscussionsWithQuestDiagnosticsInRegardOfAchievementOfAdditionalAmount
1000000
CY2012 vrml Fda Clearance Of First Diagnostic Test Kit
FdaClearanceOfFirstDiagnosticTestKit
3000000
CY2012 vrml Fda Clearance Of Up To Two Subsequent Diagnostic Test Kits
FdaClearanceOfUpToTwoSubsequentDiagnosticTestKits
2000000
CY2012 vrml Fda Clearance Of Up To Two Subsequent Diagnostic Test Kits Forgiveness
FdaClearanceOfUpToTwoSubsequentDiagnosticTestKitsForgiveness
4000000
CY2012 vrml Gain On Sale Of Instrument Business
GainOnSaleOfInstrumentBusiness
1830000
CY2012 vrml Gain On Settlement
GainOnSettlement
1000000
CY2012 vrml Increase Decrease In Reorganization Items
IncreaseDecreaseInReorganizationItems
-32000
CY2012 vrml Maximum Amount Of Application Received On Licensed Laboratory Test
MaximumAmountOfApplicationReceivedOnLicensedLaboratoryTest
3000000
CY2012 vrml Maximum Number Of Application For Licensed Laboratory Test
MaximumNumberOfApplicationForLicensedLaboratoryTest
3 Application
CY2012 vrml Repayment Of Short Term Debt
RepaymentOfShortTermDebt
5894000
CY2012 vrml Royalty Cap
RoyaltyCap
10000000
CY2012 vrml Sales Price
SalesPrice
20000000
CY2012 vrml Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.25 pure
CY2012 vrml Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Reduction In Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantReductionInGrant
251058 shares
CY2012 vrml Foreign Currency Exchange Gain Loss
ForeignCurrencyExchangeGainLoss
-153000
CY2009Q4 vrml Issuance Of Common Stock Shares In Exchange For Notes
IssuanceOfCommonStockSharesInExchangeForNotes
220000 shares
CY2012Q1 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
535000
CY2012Q1 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
379000

Files In Submission

Name View Source Status
0001193125-13-087647-index-headers.html Edgar Link pending
0001193125-13-087647-index.html Edgar Link pending
0001193125-13-087647.txt Edgar Link pending
0001193125-13-087647-xbrl.zip Edgar Link pending
d453081d10k.htm Edgar Link pending
d453081dex210.htm Edgar Link pending
d453081dex231.htm Edgar Link pending
d453081dex232.htm Edgar Link pending
d453081dex311.htm Edgar Link pending
d453081dex312.htm Edgar Link pending
d453081dex32.htm Edgar Link pending
d453081dex320.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrml-20121231.xml Edgar Link completed
vrml-20121231.xsd Edgar Link pending
vrml-20121231_cal.xml Edgar Link unprocessable
vrml-20121231_def.xml Edgar Link unprocessable
vrml-20121231_lab.xml Edgar Link unprocessable
vrml-20121231_pre.xml Edgar Link unprocessable